News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) acceptance of their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults.
The Satcher Health Leadership Institute at Morehouse School of Medicine (SHLI), with support from Otsuka America Pharmaceutical, Inc., a leader in mental health, released The Economic Burden of Mental Health Inequities in the United States Report. SHLI looked at a four-year period (2016-2020) and found, at minimum, nearly 117,000 lives and approximately $278 billion could have been saved. The full report is now available for download.
People living with serious mental illness (SMI) are at higher risk for a wide range of chronic physical conditions, are more likely to visit the emergency department, be admitted to the hospital and have longer hospital stays compared to those without SMI. Nonadherence to drug treatments for major depressive disorder (MDD), schizophrenia and bipolar disorder is common. Several studies illustrate the problem, estimating that up to half of patients with bipolar disorder, MDD and/or schizophrenia do not take their medication as directed.
Otsuka and Lundbeck presented positive results from a Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia at the 2022 Alzheimer's Association International Conference.
- Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo
- Agitation is a very prevalent clinical manifestation in Alzheimer’s dementia and one of the most complex and stressful aspects of care in patients affected by the disease. It is associated with greater caregiver burden, earlier nursing home placement, increased morbidity and mortality, and a substantial economic burden.
- Currently there are no FDA-approved pharmacological treatments for agitation in Alzheimer’s dementia